Summarized by Masters of Longevity from PR Newswire.
A preview of a conference presentation covering global clinical trial results for a new targeted therapy in EGFR‑mutated lung cancer, highlighting trial design and development plans.
Key Takeaways
- Randomized Phase 1 dose-expansion data showed higher efficacy at the 2.5 mg/kg dose level compared with lower doses.
- Safety and pharmacokinetic findings across global patients supported 2.5 mg/kg D1D8 Q3W as the recommended Phase 3 dose.
- SystImmune plans a global registrational study named IZABRIGHT-Lung01 in EGFR-mutated NSCLC after prior third-generation EGFR inhibitor treatment.
